Combination of Vancomycin and Cefazolin Lipid Nanoparticles for Overcoming Antibiotic Resistance of MRSA

Combination of Vancomycin and Cefazolin Lipid Nanoparticles for Overcoming Antibiotic Resistance of MRSA

Vancomycin is the treatment of choice for infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Clinically, combinations of vancomycin (VAN) and beta-lactams have been shown to improve patient outcomes compared to VAN alone for the treatment of MRSA bloodstream infections. However...

Full description

Bibliographic Details
Main Authors: Ketki Bhise, Samaresh Sau, Razieh Kebriaei, Seth A. Rice, Kyle C. Stamper, Hashem O. Alsaab, Michael J. Rybak, Arun K. Iyer
Format: Article
Language:English
Published: MDPI AG 2018-07-01
Series:Materials
Subjects:
vancomycin
cefazolin
liposomes
nanoparticles
MRSA
macrophage
nephrotoxicity
Online Access:http://www.mdpi.com/1996-1944/11/7/1245

Internet

http://www.mdpi.com/1996-1944/11/7/1245

Similar Items